MAD2L1 and non-small cell lung carcinoma: MAD2L1 has been identified as a potential therapeutic target gene in NSCLC (Zhou et al., 2015), and could be a promising prognostic biomarker for LUAD (MacDermed et al., 2010) and small cell lung cancer (Liao et al., 2019), however, there was no similar results in LUSC.